文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Intrathecal chemotherapy for ciltacabtagene autoleucel-associated movement and neurocognitive toxicity.

作者信息

Kelly Kaitlin, Cooperrider Jennifer H, Bishop Michael R, Kosuri Satyajit, Jakubowiak Andrzej, Derman Benjamin A

机构信息

Section of Hematology/Oncology, University of Chicago Medical Center, Chicago, IL.

The David and Etta Jonas Center for Cellular Therapy, University of Chicago, Chicago, IL.

出版信息

Blood Adv. 2025 Jul 22;9(14):3613-3616. doi: 10.1182/bloodadvances.2024015721.

DOI:10.1182/bloodadvances.2024015721
PMID:40334078
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12281119/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f852/12281119/14f7e5d818e8/BLOODA_ADV-2024-015721-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f852/12281119/88b4c4f54559/BLOODA_ADV-2024-015721-ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f852/12281119/14f7e5d818e8/BLOODA_ADV-2024-015721-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f852/12281119/88b4c4f54559/BLOODA_ADV-2024-015721-ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f852/12281119/14f7e5d818e8/BLOODA_ADV-2024-015721-gr1.jpg

相似文献

[1]
Intrathecal chemotherapy for ciltacabtagene autoleucel-associated movement and neurocognitive toxicity.

Blood Adv. 2025-7-22

[2]
Chemotherapy-induced reversal of ciltacabtagene autoleucel-associated movement and neurocognitive toxicity.

Blood. 2023-10-5

[3]
The Economic Burden of CAR T Cell Therapies Ciltacabtagene Autoleucel and Idecabtagene Vicleucel for the Treatment of Adult Patients with Relapsed or Refractory Multiple Myeloma in the US.

BioDrugs. 2022-11

[4]
Case report: Treatment of parkinsonism secondary to ciltacabtagene autoleucel using a combination dopaminergic regimen.

Front Immunol. 2024

[5]
Plain language summary of the CARTITUDE-1 study of ciltacabtagene autoleucel for the treatment of people with relapsed or refractory multiple myeloma.

Future Oncol. 2023-6

[6]
Comparative Efficacy of Ciltacabtagene Autoleucel Versus Standard-of-Care Treatments for Patients with Previously Treated Relapsed or Refractory Multiple Myeloma: A Matching-Adjusted Indirect Comparison.

Adv Ther. 2025-5-12

[7]
Patient-reported outcomes following ciltacabtagene autoleucel or standard of care in patients with lenalidomide-refractory multiple myeloma (CARTITUDE-4): results from a randomised, open-label, phase 3 trial.

Lancet Haematol. 2025-1

[8]
Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed/refractory multiple myeloma.

Blood. 2025-1-2

[9]
Ciltacabtagene autoleucel (Carvykti) for multiple myeloma.

Med Lett Drugs Ther. 2022-11-14

[10]
Cytopenias and infections following ciltacabtagene autoleucel in heavily-pretreated relapsed or refractory multiple myeloma.

Haematologica. 2025-7-10

本文引用的文献

[1]
Parkinsonism Associated with Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy.

Mov Disord Clin Pract. 2024-12

[2]
Case report: Treatment of parkinsonism secondary to ciltacabtagene autoleucel using a combination dopaminergic regimen.

Front Immunol. 2024

[3]
Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed/refractory multiple myeloma.

Blood. 2025-1-2

[4]
Parkinson-like neurotoxicity in female patients treated with idecabtagene-vicleucel.

Hemasphere. 2024-7-25

[5]
Absolute lymphocyte count after BCMA CAR-T therapy is a predictor of response and outcomes in relapsed multiple myeloma.

Blood Adv. 2024-8-13

[6]
Glucagon-like peptide-1 class drugs show clear protective effects in Parkinson's and Alzheimer's disease clinical trials: A revolution in the making?

Neuropharmacology. 2024-8-1

[7]
BCMA-CAR T-cell treatment-associated parkinsonism.

Blood. 2023-10-5

[8]
Chemotherapy-induced reversal of ciltacabtagene autoleucel-associated movement and neurocognitive toxicity.

Blood. 2023-10-5

[9]
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma.

N Engl J Med. 2023-7-27

[10]
CAR T-cell-associated neurotoxicity in central nervous system hematologic disease: Is it still a concern?

Front Neurol. 2023-4-6

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索